OABI
OmniAbยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
OABI Profile
Omniab, Inc.
A biotech company that develops and commercializes novel antibody therapeutics
5980 Horton Street, Suite 600 , Emeryville, CA 94608
--
OmniAb, Inc., was incorporated on December 14, 2015 under the laws of the State of Delaware. OmniAb's discovery platform provides pharmaceutical industry partners with access to a variety of antibody libraries and high-throughput screening technologies to enable the discovery of next-generation therapies. At the core of the OmniAb platform is their proprietary Biological Intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which are genetically modified to produce antibodies with human sequences to facilitate the development of therapeutic drug candidates in humans. OmniFlic (transgenic rats) and OmniClic (transgenic chickens) meet the industry's need for bispecific antibody applications through a common light chain method, while OmniTaur has the unique structural properties of bovine antibodies against complex targets. Established core competencies focused on ion channels and transport aircraft further differentiate their technologies and create opportunities in emerging target categories. OmniAb antibodies have been used in a variety of modes, including bispecific antibodies, antibody-drug conjugates, and more. The OmniAb technology suite spans from BI-driven library generation to cutting-edge antibody discovery and optimization, providing an efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
